JP6865933B2 - 勃起不全治療剤 - Google Patents

勃起不全治療剤 Download PDF

Info

Publication number
JP6865933B2
JP6865933B2 JP2018031340A JP2018031340A JP6865933B2 JP 6865933 B2 JP6865933 B2 JP 6865933B2 JP 2018031340 A JP2018031340 A JP 2018031340A JP 2018031340 A JP2018031340 A JP 2018031340A JP 6865933 B2 JP6865933 B2 JP 6865933B2
Authority
JP
Japan
Prior art keywords
erectile dysfunction
cells
filtrate
treatment
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018031340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019142831A5 (https=
JP2019142831A (ja
Inventor
成史 松本
成史 松本
山本　徳則
徳則 山本
祐志 堀田
祐志 堀田
和哲 木村
和哲 木村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meis Technology
Original Assignee
Meis Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meis Technology filed Critical Meis Technology
Priority to JP2018031340A priority Critical patent/JP6865933B2/ja
Priority to US16/971,738 priority patent/US20200390819A1/en
Priority to PCT/JP2019/006205 priority patent/WO2019163798A1/ja
Priority to EP19757733.1A priority patent/EP3756677A4/en
Publication of JP2019142831A publication Critical patent/JP2019142831A/ja
Publication of JP2019142831A5 publication Critical patent/JP2019142831A5/ja
Application granted granted Critical
Publication of JP6865933B2 publication Critical patent/JP6865933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018031340A 2018-02-23 2018-02-23 勃起不全治療剤 Active JP6865933B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2018031340A JP6865933B2 (ja) 2018-02-23 2018-02-23 勃起不全治療剤
US16/971,738 US20200390819A1 (en) 2018-02-23 2019-02-20 Erectile dysfunction therapeutic agent
PCT/JP2019/006205 WO2019163798A1 (ja) 2018-02-23 2019-02-20 勃起不全治療剤
EP19757733.1A EP3756677A4 (en) 2018-02-23 2019-02-20 THERAPEUTIC AGENT FOR ERECTILE DYSFUNCTION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018031340A JP6865933B2 (ja) 2018-02-23 2018-02-23 勃起不全治療剤

Publications (3)

Publication Number Publication Date
JP2019142831A JP2019142831A (ja) 2019-08-29
JP2019142831A5 JP2019142831A5 (https=) 2021-03-04
JP6865933B2 true JP6865933B2 (ja) 2021-04-28

Family

ID=67686866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018031340A Active JP6865933B2 (ja) 2018-02-23 2018-02-23 勃起不全治療剤

Country Status (4)

Country Link
US (1) US20200390819A1 (https=)
EP (1) EP3756677A4 (https=)
JP (1) JP6865933B2 (https=)
WO (1) WO2019163798A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7525840B2 (ja) 2020-01-27 2024-07-31 国立大学法人旭川医科大学 下部尿路機能障害の治療
WO2022180661A1 (ja) * 2021-02-24 2022-09-01 株式会社Meis Technology 変形性関節症又は靭帯若しくは腱の治療製剤、及びその製造方法。
WO2022018897A1 (ja) * 2021-02-24 2022-01-27 国立大学法人東海国立大学機構 皮膚保護剤
JP7720630B2 (ja) * 2022-10-19 2025-08-08 Ｄｅｘｏｎファーマシューティカルズ株式会社 微小粒子、勃起不全の予防薬または治療薬および勃起不全の改善方法
CN116036132A (zh) * 2023-01-09 2023-05-02 博品(上海)生物医药科技有限公司 冻存型异体人源脂肪间充质干细胞在制备治疗糖尿病型勃起功能障碍药物中的应用
AU2024352725A1 (en) * 2023-09-27 2026-03-19 Biolabo Co.,Ltd Method for producing exosome-containing liquid derived from mesenchymal stem cells, and pharmaceutical product containing exosome-containing liquid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739417B2 (en) 1997-05-29 2001-10-11 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
AU2641199A (en) 1998-02-27 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies for erectile dysfunction
CN1163230C (zh) 1998-12-07 2004-08-25 日产化学工业株式会社 勃起功能障碍治疗剂
WO2006006692A1 (ja) 2004-07-08 2006-01-19 Japan Science And Technology Agency 低血清培養で選択的に増殖する動物組織遍在性の分化多能性細胞
US20090304654A1 (en) * 2008-04-30 2009-12-10 Regents Of The University Of California Methods for isolating adipose-derived stem cells and therapeutic use thereof
US9144584B2 (en) * 2008-06-11 2015-09-29 Cell4Vet Corporation Adipose tissue-derived stem cells for veterinary use
US8808688B2 (en) * 2009-10-06 2014-08-19 National University Corporation Nagoya University Cell preparation for erectile dysfunction or sensory disorders of the lower urinary tract containing adipose tissue derived mesenchymal stem cells
KR101178032B1 (ko) * 2012-04-24 2012-08-29 주식회사 티아라줄기세포연구소 지방줄기세포 파쇄 추출액을 이용한 모발증식제재 및 이의 제조방법
CN113583951A (zh) * 2012-06-26 2021-11-02 细胞创新知识产权有限公司 通过超声空化从脂肪组织分离干细胞及使用方法
CN104324053B (zh) * 2014-09-28 2018-09-11 严玉霖 一种快速愈合犬创伤组织的犬干细胞分泌因子修复液
KR101781526B1 (ko) * 2015-10-13 2017-09-26 주식회사 티아라줄기세포연구소 줄기세포 성분추출물을 포함하는 탈모치료제 제조방법
CN105902568A (zh) * 2016-04-29 2016-08-31 张宁 用于治疗勃起功能障碍的脂肪间充质干细胞
JP2018031340A (ja) 2016-08-26 2018-03-01 マツダ株式会社 エンジンの燃料性状判定装置および燃焼制御装置
CN107412264A (zh) * 2017-05-10 2017-12-01 健生生物技术有限公司 用于治疗男性勃起障碍的药物及其制备和使用方法
CN107669703A (zh) * 2017-10-25 2018-02-09 安徽科门生物科技有限公司 一种茯苓生物活性物质与人源干细胞活性因子组合物及其制备方法
JP6999196B2 (ja) * 2018-07-04 2022-01-18 正典 佐伯 幹細胞濾液製剤及びその調製方法

Also Published As

Publication number Publication date
EP3756677A4 (en) 2021-10-20
US20200390819A1 (en) 2020-12-17
WO2019163798A1 (ja) 2019-08-29
JP2019142831A (ja) 2019-08-29
EP3756677A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP6865933B2 (ja) 勃起不全治療剤
Suzuki et al. Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease
Figliuzzi et al. Bone marrow–derived mesenchymal stem cells improve islet graft function in diabetic rats
KR101578591B1 (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
Shan et al. Combination of low-energy shock-wave therapy and bone marrow mesenchymal stem cell transplantation to improve the erectile function of diabetic rats
JP5633859B2 (ja) 脂肪組織由来間葉系幹細胞を含有する免疫抑制剤及びその用途
Xie et al. Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats
JPWO2009031606A1 (ja) 関節炎治療及び予防剤
EP3299451B1 (en) Methods of using adipose tissue-derived cells in the treatment of raynaud's phenomenon
Albersen et al. Stem cell therapy for erectile dysfunction: progress and future directions
Hu et al. Effects of administration route of adipose-derived stem cells on the survival of allogeneic skin grafts in mice
JP6994729B1 (ja) 変形性関節症又は靭帯若しくは腱の治療製剤、及びその製造方法。
Lonyai et al. The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases
Bouglé et al. Beneficial role of adipose‐derived mesenchymal stem cells from microfragmented fat in a murine model of duchenne muscular dystrophy
KR102450790B1 (ko) 체세포로부터 분화된 신규한 유사신경교세포, 이의 제조 방법, 이의 제조용 칵테일 조성물, 이를 포함하는 신경 질환 예방 또는 치료용 세포 치료제 및 이를 투여하여 신경 질환을 예방 및 치료하는 방법
JP7525840B2 (ja) 下部尿路機能障害の治療
CN114762697B (zh) 用于治疗糖尿病的药物及方法
CN120076810A (zh) 微粒、勃起功能障碍的预防药或治疗药和勃起功能障碍的改善方法
Hendawy et al. Cultured versus freshly isolated adipose-derived stem cells in improvement of the histopathological outcomes in HCL-induced cystitis in a rat model
Barriga et al. Intravenous infusion of adult adipose tissue stem cells for repairing spinal cord ischaemic lesions. An experimental study on animals
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
Wiriyabanditkul et al. Amniotic fluid stem cell therapy improves erectile function in a diabetic rat model
Ahn et al. Scaffold implantation vs. intravenous delivery: a comparative preclinical animal study evaluating peroxisome proliferator-activated receptor gamma coactivator 1-alpha adipose-derived stem cells in liver fibrosis treatment
WO2007011960A3 (en) Methods and agents to treat autoimmune diseases
JP2025095535A (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180306

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200526

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200925

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210119

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210119

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210330

R150 Certificate of patent or registration of utility model

Ref document number: 6865933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250